The report highlights UCB's commitment to creating value for patients, communities and the planet. The report covers a wide range of topics including UCB's progress on sustainable performance, innovation, employee development and its global operations. Specific highlights include reaching over 400 000 patients with osteoporosis, securing reimbursement for EVENITY® in several countries, integrating Zogenix into the UCB family and launching FINTEPLA® in the EU and the U.S. The report also outlines UCB's commitment to creating a sustainable business and its ambition to reach carbon neutrality by 2030. In addition, the report includes information on UCB's compliance program, risk management strategy and its social impact initiatives.
Issuing Company UCB S.A.
Report Type Integrated Report
Report Language EN
Report Filesize 14.88 MB
No. of Pages 346 pages
Reporting periodJanuary 1, 2022-December 31, 2022
Report EditionUnknown
Assurance Provider Independent limited assurance provided by Mazars
Reporting Standards GRI; SASB Standards
Materiality Assessmenttrue
